Study on the mechanism of Kechuanliuwei Oral Liquid prepared by new technology in the treatment of asthmatic mice
YANG Fanping XI Yan▲
1.Office of Clinical Trial Institution, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200062;
2.Department of Pharmacy, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032
Abstract：Objective To observe the effect of Kechuanliuwei Oral Liquid prepared by new technology on asthmatic mice and to explore its anti-asthma mechanism. Methods According to the random number table method, the mice were divided into control group, asthma model group, Kechuanliuwei Oral Liquid (new technology) low-dose group (15.5 g/kg), Kechuanliuwei Oral Liquid (new technology) high-dose group (31 g/kg), Dexamethasone group (3 g/kg), with six mice in each group. Except for control group, the other groups were treated with ovalbumin (OVA) to establish asthma model. Each group was given intragastric administration of drug from day 21 of modeling, at the same time, atomization excitation was given. Airway reactivity was measured by pulmonary function meter; pathological changes of lung tissue were observed by HE staining; serum interleukin (IL)-13, IL-17 and interferon-γ (IFN-γ) were measured by enzyme-linked immunosorbent assay. Results Asthma model group, Kechuanliuwei Oral Liquid (new technology) low-dose group, Kechuanliuwei Oral Liquid (new technology) high-dose group and Dexamethasone group were all successfully atomized to induce asthma. When Acetylcholine concentration was 6.250, 12.500, 50.000 mg/ml, the Penh value of asthma model group were higher than those of control group, and the differences were statistically significant (P < 0.05); Penh values of Kechuanliuwei Oral Liquid (new technology) low-dose group, Kechuanliuwei Oral Liquid (new technology) high-dose group and Dexamethasone group were lower than those of asthma model group, and the differences were statistically significant (P < 0.05). In control group, the lung tissue structure was clear and complete, and the bronchus and alveoli were normal, without obvious inflammatory cells. In asthmatic model group, the lung tissue structure was disordered, and the bronchus became narrow and thick, surrounded by inflammatory cells. The lung tissues of mice in Kechuanliuwei Oral Liquid (new technology) low-dose group, Kechuanliuwei Oral Liquid (new technology) high-dose group and Dexamethasone group were slightly changed with good structure; and the bronchus were all deformed to different degrees, but the degree of narrowing and thickening was less than that of asthma model group, and there were a few inflammatory cells. There were no significant differences in serum IL-13, IL-17, and IFN-γ levels between asthma model group and control group (P > 0.05). The serum levels of IL-13, IL-17, and IFN-γ in Kechuanliuwei Oral Liquid (new technology) low-dose group, Kechuanliuwei Oral Liquid (new technology) high-dose group and Dexamethasone group were not significantly different from those in asthma model group (P > 0.05). Conclusion Kechuanliuwei Oral Liquid prepared by new technology can improve the airway reactivity, pathological damage of lung tissue and inflammatory response in asthmatic mice.
杨帆平1 奚燕2▲. 新工艺制备的咳喘六味合剂治疗哮喘小鼠的作用机制研究[J]. 中国医药导报, 2021, 18(22): 37-40,45.
YANG Fanping XI Yan▲. Study on the mechanism of Kechuanliuwei Oral Liquid prepared by new technology in the treatment of asthmatic mice. 中国医药导报, 2021, 18(22): 37-40,45.
京公网安备 11010502046598号